Fairmont Chateau Lake Louise Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2007



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Antibodies as Drugs: From Basic Biology to the Clinic (B2)


Organizer(s) Jochen G. Salfeld and Karl Dane Wittrup
February 1—6, 2007
Fairmont Chateau Lake Louise • Lake Louise, AB Canada
Abstract Deadline: Oct 2, 2006
Late Abstract Deadline: Nov 1, 2006
Scholarship Deadline: Oct 2, 2006
Early Registration Deadline: Dec 1, 2006

Sponsored by Abbott Laboratories

Summary of Meeting:
Therapeutic antibodies have become important components of standard care in some areas of clinical practice, but lag behind in others. What can be learned from prior successes and failures of antibody drug development? Interdisciplinary discussions spanning immunobiology, protein engineering, bioprocess development, pharmacokinetics, and clinical medicine for neurological disease, infectious diseases, immunological diseases, and cancer should help identify crosscutting themes and general approaches.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


THURSDAY, FEBRUARY 1

15:00—19:30
Registration

Mt. Temple Foyer
18:30—19:30
Refreshments

Mt. Temple Foyer
19:30—19:45
Opening Remarks

Mt. Temple A-B
* Jochen G. Salfeld, Abbott, USA

19:45—20:45
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Mt. Temple A-B
Jeffrey V. Ravetch, Rockefeller University, USA
Mechanism of Therapeutic Antibodies


FRIDAY, FEBRUARY 2

07:00—08:00
Breakfast

Victoria Dining Room
08:00—11:00
Therapeutic Antibody Effector Functions
Meeting has ended...abstracts no longer viewable online.

Mt. Temple A-B
* Jochen G. Salfeld, Abbott, USA

Michael C. Carroll, Boston Children's Hospital, Harvard Medical School, USA
Natural IgM as a Mediator of Innate Autoimmunity

Birgitta Heyman, Uppsala University, Sweden
Regulation of Antibody Responses via Antibodies, Fc Receptors and Complement

P. Mark Hogarth, Burnet Institute, Australia
Short Talk: Structural and in vivo Analyses of FcgammaRIIa to Define Unique Approaches for the Development of Therapeutic Antibodies and Anti-Inflammatory Compounds

Eugenia Corrales-Aguilar, Heinrich-Heine-University, Düsseldorf, Germany
Short Talk: Receptor-selective Inhibition of IgG-mediated Effector Functions through Herpesviral FcgammaReceptors

Shigeru Iida, Kyowa Hakko Chemical Co., Japan
Short Talk: Non-Fucosylated Therapeutic IgG1 Antibody can Evade the Inhibitory Effect of Serum IgG on Antibody-Dependent Cellular Cytotoxicity Through its High Binding to FcgammaRIIIa

Phil Hammond, Zymeworks, USA
Beyond ADCC: Fc Engineered Antibodies with Broadly Improved Function Including Enhanced Phagocytosis

09:20—09:40
Coffee Break

Mt. Temple Foyer
11:15—13:00
Poster Setup

Mt. Temple C
13:00—22:00
Poster Viewing

Mt. Temple C
14:30—16:30
Workshop: Targeting of Therapeutic Antibodies

Mt. Temple A-B
* E. Sally Ward, University of Texas Southwestern Medical Center, USA

* Eric V. Shusta, University of Wisconsin, Madison, USA

Greg Thurber, Massachusetts Institute of Technology, USA
Internalization and Clearance Limit Antibody Uptake – An Experimental and Theoretical Analysis

Paul A. Ramsland, RMIT University, Australia
Structural Studies in Antibody Recognition of Type 2 Lewis Carbohydrates and Implications for Cancer Immunotherapy

Michael M. Schmidt, Massachusetts Institute of Technology, USA
Engineering Antibody Fragments for Improved Targeting of Solid Tumors and Micrometastases

Gerard Zurawski, Baylor Institute for Immunology Research, USA
Anti-Dendritic Cell Receptor Recombinant Antibodies Fused to Cancer and Viral Antigens Effectively Target the Antigens to Human Dendritic Cells and Elicit Potent Immune Responses

Esther Breij, Genmab, Netherlands
Chimeric Surfactant Protein D/anti-Fc Receptor Proteins as a Tool to Enhance Host Defense Against Infections

Liming Liu, Merck, USA
Amelioration of Experimental Autoimmune Myasthenia Gravis (EAMG) in Rats by FcRn Blockade

16:30—17:00
Coffee Available

Mt. Temple Foyer
17:00—19:00
New Antibody Engineering Technologies
Meeting has ended...abstracts no longer viewable online.

Mt. Temple A-B
* Karl Dane Wittrup, Massachusetts Institute of Technology, USA

Andreas G. Plückthun, University of Zürich, Switzerland
Tumor Tagerting with Ankyrin Repeat Proteins

Ian M. Tomlinson, GlaxoSmithKline, UK
Domain Antibodies: Half-Life Extension and Dual Targeting Antibodies

John Löfblom, Royal Institute of Technology, School of Biotechnology, Sweden
Short Talk: Staphylococcal Surface Display in Combinatorial Bioengineering

Antonio Lanzavecchia, Institute for Research in Biomedicine, Switzerland
Human Monoclonal Antibodies from Memory B Cells

19:00—20:00
Social Hour with Lite Bites

Mt. Temple C
19:30—22:00
Poster Session 1

Mt. Temple C

SATURDAY, FEBRUARY 3

07:00—08:00
Breakfast

Victoria Dining Room
08:00—11:00
Antibody Manufacturing and Formulation
Meeting has ended...abstracts no longer viewable online.

Mt. Temple A-B
* George C. Avgerinos, Fortress Biotech, Inc., USA
Trends in Large-Scale Antibody Manufacture

Alexis T. Henry, Diosynth Biotechnology, USA
Short Talk: Development of Antibody Producing Chinese Hamster Ovary Cell Lines by Traditional and Non-Traditional Methods

David P. Humphreys, UCB Pharma, UK, UK
Antibody Fab’ Fragments: Expression and Purification from E. coli, PEGylation and Clinical Uses.

Yi Wang, Alexion Pharmaceuticals, Inc., USA
Short Talk: Nebulization administration of anti-C5 mAb on the Development of Airway Hyperresponsiveness (AHR)

Jun Liu, Genentech, Inc., USA
Challenges and Issues in the Development of High Concentration Monoclonal Antibody Formulations

09:20—09:40
Coffee Break

Mt. Temple Foyer
11:00—13:00
Poster Setup

Mt. Temple C
13:00—22:00
Poster Viewing

Mt. Temple C
16:30—17:00
Coffee Available

Mt. Temple Foyer
17:00—19:00
Antibody Pharmacokinetics
Meeting has ended...abstracts no longer viewable online.

Mt. Temple A-B
* E. Sally Ward, University of Texas Southwestern Medical Center, USA
Molecular Mechanisms of IgG Homeostasis: Implications for Modulating Pharmacokinetics of Therapeutic Antibodies

Inger Sandlie, University of Olso, Norway
Short Talk: The Conserved H166 Residue of Human FcRn Heavy Chain is Critical for the pH Dependent Binding to Albumin that Occurs Independently of IgG Binding

Steven M. Larson, Memorial Sloan-Kettering Cancer Center, USA
Imaging and Therapy with Radiolabeled Antibodies

David J. King, aTyr Pharma, Inc., USA
Human Antibody Alkylating Agent Conjugates for Cancer Therapy

19:00—20:00
Social Hour with Lite Bites

Mt. Temple C
19:30—22:00
Poster Session 2

Mt. Temple C

SUNDAY, FEBRUARY 4

07:00—08:00
Breakfast

Victoria Dining Room
08:00—11:15
Cancer
Meeting has ended...abstracts no longer viewable online.

Mt. Temple A-B
Richard H.J. Begent, University College London, UK
Lessons from Antibody-Directed Enzyme Prodrug Therapy (ADEPT)

Ling Liu, Eli Lilly and Company, USA
Short Talk: Antagonist Antibodies to Interleukin 17 Reduces Plasma KC and Tumor Growth

Dario Neri, ETH Zürich, Switzerland
Vascular Targeting with Recombinant Antibody Derivatives

Andrew M. Scott, Ludwig Institute for Cancer Research, Australia
Targeting a Tumor Specific Epitope of the Epidermal Growth Factor Receptor

William M. Siders, Genzyme Corporation, USA
Short Talk: In Vitro and in Vivo Analysis of the Mechanism of Action of Campath (Alemtuzumab)

* Louis M. Weiner, Georgetown University Medical Center, USA
Influence of Antibody Structure on Tumor Targeting and Immune Mediated Tumor Lysis

09:20—09:40
Coffee Break

Mt. Temple Foyer
13:00—14:30
Panel Discussion: Lessons from TGN1412 Phase I Trial

Mt. Temple A-B
* Lars Klareskog, Karolinska Institutet, Sweden
Panelists will be selected from symposium attendees prior to the meeting.

Richard H.J. Begent, University College London, UK

Steven M. Larson†, Memorial Sloan-Kettering Cancer Center, USA

Jochen G. Salfeld, Abbott, USA

14:30—15:00
Coffee Available

Mt. Temple Foyer
15:00—17:00
Neuroscience
Meeting has ended...abstracts no longer viewable online.

Mt. Temple A-B
Eric V. Shusta, University of Wisconsin, Madison, USA
Blood-Brain Barrier Models and New Transporter Discovery

Eliezer Masliah, University of California, San Diego, USA
Novel Approaches to Alzheimer Therapy

Joseph F. Poduslo, Mayo Clinic, USA
Short Talk: In Vivo Targeting of Antibody Fragments to the Nervous System for Alzheimer’s Disease Immunotherapy and Molecular Imaging of Amyloid Plaques

* Arnon Rosenthal, Alector, USA
Experience with Therapeutic Antibodies for Pain


MONDAY, FEBRUARY 5

07:00—08:00
Breakfast

Victoria Dining Room
08:00—11:45
Autoimmunity, Allergy and Asthma
Meeting has ended...abstracts no longer viewable online.

Mt. Temple A-B
* Paul P. Tak, GlaxoSmithKline, UK
Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Disease

Cornelia M. Weyand, Emory University School of Medicine, USA
Mechanisms of B cell-targeted Therapeutic Approaches in Rheumatoid Arthritis

Michael Panzara, Biogen Idec, Inc., USA
Development of Natalizumab: A Case Study

Steven G. Nadler, Bristol-Myers Squibb Company, USA
Treating Autoimmune Disease with Co-Stimulation Inhibitors

Csaba C. Pazmany, Dyax Corporation, USA
Short Talk: Role of Tissue Kallikrein 1 in Airway Inflammation

Helena Persson, Lund University, Sweden
Short Talk: The IgE Repertoire in Grass Pollen Allergy – Specificity and Diversity

Lars Klareskog, Karolinska Institutet, Sweden
Assessment of Long Term Effectiveness and Safety of Therapeutic Antibodies

09:20—09:40
Coffee Break

Mt. Temple Foyer
16:30—17:00
Coffee Available

Mt. Temple Foyer
17:00—18:45
Infectious Disease
Meeting has ended...abstracts no longer viewable online.

Mt. Temple A-B
* James D. Marks, University of California, San Francisco, USA
Anti-Botulism Toxin Antibody Engineering

Michael S. Diamond, Washington University School of Medicine, USA
The Molecular Basis of Antibody-Mediated Neutralization of West Nile Virus

Dennis R. Burton, The Scripps Research Institute, USA
Antibodies in Antiviral Vaccine Development

18:45—19:00
Closing Remarks and Summary
Meeting has ended...abstracts no longer viewable online.

Mt. Temple A-B
Karl Dane Wittrup, Massachusetts Institute of Technology, USA

19:00—20:00
Social Hour with Lite Bites

Victoria
20:00—23:00
Entertainment

Victoria

TUESDAY, FEBRUARY 6

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1 R13 CA124284-01




National Institutes of Health

Grant No. 1 U13 AI60000-01




We gratefully acknowledge additional support for this conference from:

Abbott Laboratories UCB Celltech
Varian, Inc.
 

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Biogen Idec


Bristol-Myers Squibb Company


Domantis Limited


UCB Celltech


Abbott Bioresearch Center


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676